craigakess, you posted a Yahoo article about Enher
Post# of 148015
The drug, which is administered as an intravenous infusion, is not without safety concerns. It has been linked to a type of lung scarring called interstitial lung disease (ILD). Forty-five Enhertu patients in the trial had varying degrees of ILD versus one in the chemotherapy group.
Enhertu belongs to class of therapies called antibody drug conjugates (ADC), which are engineered antibodies that bind to tumour cells and release cell-killing chemicals.
https://www.reuters.com/business/healthcare-p...022-06-05/